TIAA CREF Investment Management LLC reduced its position in shares of Myovant Sciences Ltd (NASDAQ:MYOV) by 8.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 17,523 shares of the company’s stock after selling 1,593 shares during the quarter. TIAA CREF Investment Management LLC’s holdings in Myovant Sciences were worth $206,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the stock. Wells Fargo & Company MN increased its holdings in Myovant Sciences by 331.9% during the 1st quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock worth $194,000 after purchasing an additional 12,700 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Myovant Sciences by 36.3% in the first quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock valued at $279,000 after acquiring an additional 6,330 shares in the last quarter. Oxford Asset Management bought a new position in shares of Myovant Sciences in the first quarter valued at approximately $303,000. JPMorgan Chase & Co. grew its holdings in shares of Myovant Sciences by 30.6% in the first quarter. JPMorgan Chase & Co. now owns 83,070 shares of the company’s stock valued at $975,000 after acquiring an additional 19,474 shares in the last quarter. Finally, BB Biotech AG grew its holdings in shares of Myovant Sciences by 3.4% in the first quarter. BB Biotech AG now owns 3,302,835 shares of the company’s stock valued at $38,775,000 after acquiring an additional 110,000 shares in the last quarter.
COPYRIGHT VIOLATION NOTICE: “TIAA CREF Investment Management LLC Cuts Stake in Myovant Sciences Ltd (MYOV)” was originally reported by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://baseballnewssource.com/markets/myovant-sciences-ltd-myov-shares-sold-by-tiaa-cref-investment-management-llc/1566163.html.
Several equities analysts have recently issued reports on the company. Zacks Investment Research raised Myovant Sciences from a “sell” rating to a “hold” rating in a report on Thursday, September 7th. Evercore ISI assumed coverage on Myovant Sciences in a report on Wednesday, August 16th. They set an “outperform” rating for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Myovant Sciences has a consensus rating of “Buy” and an average target price of $18.20.
Myovant Sciences Ltd (NASDAQ MYOV) traded down 0.64% during midday trading on Friday, hitting $12.47. The company’s stock had a trading volume of 30,568 shares. The firm’s market cap is $758.72 million. The company’s 50 day moving average price is $12.59 and its 200 day moving average price is $12.15. Myovant Sciences Ltd has a 12 month low of $10.25 and a 12 month high of $14.27.
Myovant Sciences Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with our FREE daily email newsletter.